Drug intelligence / Profile preview

buprenorphine + naloxone

Development stage
Approved
Lead developer
Indivior
Modality
Small Molecules
Administration
Buccal, Intravenous, Sublingual
01

Overview

Buprenorphine + naloxone is a fixed-dose combination medication used primarily for the treatment of opioid use disorder. Buprenorphine acts as a partial agonist at the μ-opioid receptor, providing enough opioid effect to prevent withdrawal symptoms and cravings but with a ceiling effect that reduces overdose risk. Naloxone is an opioid antagonist included to deter misuse; it has poor oral/sublingual bioavailability but can precipitate withdrawal if injected, discouraging intravenous abuse. The combination is indicated for both induction and maintenance therapy in opioid dependence, reducing mortality associated with opioid use disorder[1][2][3][5][6].

Brand names
SuboxoneZubsolv
Other names
buprenorphine/naloxonebuprenorphine and naloxone
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on buprenorphine + naloxone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on buprenorphine + naloxone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call